Differential effects of an NR2B NAM and ketamine on synaptic potentiation and gamma synchrony: Relevance to rapid-onset antidepressant efficacy

Neuropsychopharmacology

Volumn 41, Issue 6, 2016, Pages 1486-1494

  Nagy, Dávid ^a   Stoiljkovic, Milan ^a   Menniti, Frank S ^b   Hajós, Mihály ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mnemosyne Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KETAMINE; TRAXOPRODIL; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR2B NMDA RECEPTOR; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY SYSTEM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; EVOKED AUDITORY RESPONSE; HIPPOCAMPUS; NEUROPHYSIOLOGY; NONHUMAN; OSCILLATION; PRIMARY AUDITORY CORTEX; PRIORITY JOURNAL; RAT; SYNAPTIC POTENTIAL; ALLOSTERISM; ANIMAL; ANTAGONISTS AND INHIBITORS; AUDITORY CORTEX; AUDITORY EVOKED POTENTIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; GAMMA RHYTHM; MALE; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SYNAPSE;

ALLOSTERIC REGULATION; ANIMALS; ANTIDEPRESSIVE AGENTS; AUDITORY CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EVOKED POTENTIALS, AUDITORY; EXCITATORY AMINO ACID ANTAGONISTS; GAMMA RHYTHM; HIPPOCAMPUS; KETAMINE; MALE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES;

EID: 84963576931     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.298     Document Type: Article

References (44)

1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351-354
2. Chenard BL, Bordner J, Butler TW, Chambers LK, Collins MA, De Costa DL, et al. (1995). (1S, 2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-Aspartate responses. J Med Chem 38: 3138-3145
3. Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, et al. (2012). Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry 72: 555-561
4. Dix S, Gilmour G, Potts S, Smith JW, Tricklebank M. (2010). A within-subject cognitive battery in the rat: differential effects of NMDA receptor antagonists. Psychopharmacology 212: 227-242
5. Dworak M, McCarley RW, Kim T, Basheer R. (2011). Delta oscillations induced by ketamine increase energy levels in sleepwake related brain regions. Neuroscience 197: 72-79
6. Fu Y, Guo L, Zhang J, Chen Y, Wang X, Zeng T, et al. (2008). Differential effects of ageing on the EEG during pentobarbital and ketamine anaesthesia. Eur J Anaesthesiol 25: 826-833
7. Gass N, Schwarz AJ, Sartorius A, Schenker E, Risterucci C, Spedding M, et al. (2014). Sub-Anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat. Neuropsychopharmacology 39: 895-906
8. Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, et al. (2012). NMDA receptors, cognition and schizophrenia-Testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 62: 1401-1412
9. Hajós M. (2006). Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol Sci 27: 391-398
10. Hajós M, Hoffmann WE, Kocsis B. (2008). Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry 63: 1075-1083
11. Harvey BD, Siok CJ, Kiss T, Volfson D, Grimwood S, Shaffer CL, et al. (2013). Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors. Neuropharmacology 75: 19-30
12. Hong LE, Summerfelt A, Buchanan RW, O'Donnell P, Thaker GK, Weiler MA, et al. (2010). Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 35: 632-640
13. Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, et al. (2011). Translating glutamate: from pathophysiology to treatment. Sci Transl Med 3: 102mr102
14. Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajós M. (2008). Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 7: 68-83
15. Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D. (2012). Has an angel shown the way?. Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull 38: 958-966
16. Karakas E, Simorowski N, Furukawa H. (2011). Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors. Nature 475: 249-253
17. Kiss T, Feng J, Hoffmann WE, Shaffer CL, Hajós M. (2013). Rhythmic theta and delta activity of cortical and hippocampal neuronal networks in genetically or pharmacologically induced N-methyl-D-Aspartate receptor hypofunction under urethane anesthesia. Neuroscience 237: 255-267
18. Kiss T, Hoffmann WE, Hajós M. (2011). Delta oscillation and shortterm plasticity in the rat medial prefrontal cortex: modelling NMDA hypofunction of schizophrenia. Int J Neuropsychopharmacol 14: 29-42
19. Kittelberger K, Hur EE, Sazegar S, Keshavan V, Kocsis B. (2012). Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia. Brain Struct Funct 217: 395-409
20. Kocsis B. (2012). Differential role of NR2A and NR2B subunits in N-methyl-D-Aspartate receptor antagonist-induced aberrant cortical gamma oscillations. Biol Psychiatry 71: 987-995
21. Kocsis B. (2012). State-dependent increase of cortical gamma activity during REM sleep after selective blockade of NR2B subunit containing NMDA receptors. Sleep 35: 1011-1016
22. Kocsis B, Brown RE, McCarley RW, Hajós M. (2013). Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits. CNS Neurosci Ther 19: 437-447
23. Krystal JH, Sanacora G, Duman RS. (2013). Rapid-Acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73: 1133-1141
24. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964
25. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. (2011). Glutamate N-methyl-D-Aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69: 754-761
26. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. (2015). A systematic review and meta-Analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 45: 693-704
27. Menniti F, Chenard B, Collins M, Ducat M, Shalaby I, White F. (1997). CP-101, 606, a potent neuroprotectant selective for forebrain neurons. Eur J Pharmacol 331: 117-126
28. Moghaddam B, Krystal JH. (2012). Capturing the angel in angel dust: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull 38: 942-949
29. Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, et al. (1998). Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1: 659-667
30. Nagy D, Tingley FD, Stoiljkovic M, Hajós M. (2015). Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor. Exp Neurol 263: 122-131
31. Nutt JG, Gunzler SA, Kirchhoff T, Hogarth P, Weaver JL, Krams M, et al. (2008). Effects of a NR2B selective NMDA glutamate antagonist, CP-101, 606, on dyskinesia and Parkinsonism. Mov Disord 23: 1860-1866
32. Paxinos G, Watson C. (1998). The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press: San Diego, CA, USA
33. Pinault D. (2008). N-methyl d-Aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex. Biol Psychiatry 63: 730-735
34. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-Daspartate antagonist, CP-101, 606, in patients with treatmentrefractory major depressive disorder. J Clin Psychopharmacol 28: 631-637
35. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, et al. (2014). Lanicemine: a low-Trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 19: 978-985
36. Shaffer CL, Osgood SM, Smith DL, Liu J, Trapa PE. (2014). Enhancing ketamine translational pharmacology via receptor occupancy normalization. Neuropharmacology 86: 174-180
37. Siok CJ, Cogan SM, Shifflett LB, Doran AC, Kocsis B, Hajós M. (2012). Comparative analysis of the neurophysiological profile of group II metabotropic glutamate receptor activators and diazepam: effects on hippocampal and cortical EEG patterns in rats. Neuropharmacology 62: 226-236
38. Sivarao DV, Chen P, Yang Y, Li YW, Pieschl R, Ahlijanian MK. (2014). NR2B antagonist CP-101, 606 abolishes pitch-mediated deviance detection in awake rats. Front Psychiatry 5: 96
39. Smith JW, Gastambide F, Gilmour G, Dix S, Foss J, Lloyd K, et al. (2011). A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology 217: 255-269
40. Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT. (2000). Antiparkinsonian actions of CP-101, 606, an antagonist of NR2B subunit-containing N-methyl-d-Aspartate receptors. Exp Neurol 163: 239-243
41. Taniguchi K, Shinjo K, Mizutani M, Shimada K, Ishikawa T, Menniti FS, et al. (1997). Antinociceptive activity of CP-101, 606, an NMDA receptor NR2B subunit antagonist. Br J Pharmacol 122: 809-812
42. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. (2010). Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62: 405-496
43. Wang M, Yang Y, Wang CJ, Gamo NJ, Jin LE, Mazer JA, et al. (2013). NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex. Neuron 77: 736-749
44. Zhang Y, Yoshida T, Katz DB, Lisman JE. (2012). NMDAR antagonist action in thalamus imposes delta oscillations on the hippocampus. J Neurophysiol 107: 3181-3189